D-JNKI-1

Research use only, not for human use.

A cell-permeable peptide inhibitor of JNK kinase.

A cell-permeable peptide inhibitor of JNK kinase; blocks apoptotic JNK signaling in brain mitochondria; decreases the expression of CD4(+) and CD8(+) cells, effects T-cell activation, differentiation, and migration in a murine model of chronic colitis; prevents hearing loss from SC transection in the guinea pig model of PA-OM.Other Indication Phase 3 Clinical.

D-JNKI-1 (AM-111; 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells.

D-JNKI-1 (AM-111; 10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice.

Brimapitide | AM-111 | XG-102

MAPK/ERK Signaling

JNK

JNK

Other Indications

Other Disease

1445179-97-4

3822.44

C164H286N66O40

>98% (HPLC)

H2O: >50 mg/mL

CC(C)CC(C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)N2CCCC2C(=O)NC(CCCNC(=N)N)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)N)NC(=O)C(CC5=CC=CC=C5)NC(=O)C6CCCN6C(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)O)N

NH2-DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-COOH

(-20℃)

With Ice Pack

≥ 2 years